Latest News and Press Releases
Want to stay updated on the latest news?
-
Preclinical study will be conducted by Dr. David Reardon’s research groupImmune-activating small molecule INV501 will be tested as treatment for aggressive brain cancer VIENNA, Austria and BOSTON,...
-
INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indicationsTreatment with INV501 significantly inhibits tumor...